Accelleron lifts 2026 outlook, sees 14%-17% organic revenue growth
Reuters2026/08/27 04:59- Accelleron raised 2026 guidance to 14-17% organic revenue growth, reflecting structural demand strength, particularly in energy.
- Operational EBITA margin forecast lifted to 25-26%.
- Outlook update follows H1 revenue of USD 737 million, up 21.3% year-on-year, with operational EBITA of USD 190 million.
- Data center-related revenue rose to slightly below 9% of H1 sales, driven by U.S. gas-fired prime power demand.
- Capital expenditure expected at about 5-6% of 2026 revenue to expand capacity, upgrade manufacturing and R&D, support growth.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cambria Gold Mines FY26 Q2 net loss narrows to CAD 2.96 million
TRUMP rises nearly 8% in 24 hours, market capitalization reaches $2.037 billions
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Crypto prices
More
